LSE - Delayed Quote GBp

Hikma Pharmaceuticals PLC (HIK.L)

1,813.00

-6.00

(-0.33%)

At close: 4:35 PM GMT+1

With 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big guns

Key Insights Significantly high institutional ownership implies Hikma Pharmaceuticals' stock price is sensitive to...

Simply Wall St. 9 days ago

HKMPF

HKMPY
Optimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past week

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Simply Wall St. last month

HKMPY
Merck's Bridion faces generic threat from drugmaker Hikma

Merck has received a letter that Hikma Pharmaceuticals US unit has sought a pre-patent expiry approval from the US FDA to sell a generic version of its Bridion injection, the drugmaker said in filing on Monday. Merck said, on Feb. 5, it received the letter under the Hatch-Waxman Act, through which a company can seek FDA approval to market a copycat before the expiration of patents related to the brand-name drug. Merck said in the filing that it is currently considering its options.

Reuters last month

HKMPY
Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today welcomed Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy (ONDCP), to its Columbus, Ohio manufacturing facility for a visit and important dialogue on the US opioid overdose epidemic and Hikma's and ONDCP's shared goal of expanding the availability and awareness of life-saving naloxone.

PR Newswire 2 months ago

HKMPF

HKMPY
High-dose opioid reversal spray no better than lower dose in field, US study finds

A high-dose version of the opioid reversal spray naloxone, made by Hikma Pharmaceuticals, did not result in an increased survival rate compared with lower-dose versions of the drug when administered in emergency situations by New York law enforcement, according to a U.S. study. The analysis also suggests that those given the higher 8 milligram strength spray were more than twice as likely to experience opioid withdrawal symptoms compared to other sprays such as Narcan that use a 4 mg dose. The Hikma version, sold under the brand name Kloxxado, was approved in 2021 after U.S. Food and Drug Administration advisers and National Institutes of Health reports suggested that a high-dose version was needed to respond to overdoses by more potent opioids such as fentanyl.

Reuters 2 months ago

HKMPY
Hikma announces US launch of COMBOGESIC® IV

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the launch of COMBOGESIC® IV (acetaminophen and ibuprofen) injection in the US.

PR Newswire 2 months ago

HKMPF

HKMPY
UPDATE 1-Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 million

A division of French advertising company Publicis Groupe SA and drug company Hikma Pharmaceuticals have reached separate settlements worth a collective $500 million to resolve claims that they helped fuel the deadly U.S. opioid epidemic. The settlements announced by U.S. state attorneys general on Thursday add to the more than $50 billion that drug manufacturers, distributors, pharmacy operators and consultants have agreed to pay to resolve lawsuits and investigations over their roles in the drug addiction crisis. Publicis Health, a subsidiary of Publicis Groupe, agreed to pay $350 million to resolve claims by all U.S. states and territories that it helped OxyContin maker Purdue Pharma devise marketing strategies to boost sales of its prescription opioid painkiller.

Reuters 2 months ago

HKMPY

PUBGY
Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 million

BOSTON (Reuters) -A division of French advertising company Publicis Groupe SA and drug company Hikma Pharmaceuticals have reached separate settlements worth a collective $500 million to resolve claims that they helped fuel the deadly U.S. opioid epidemic. The settlements announced by U.S. state attorneys general on Thursday add to the more than $50 billion that drug manufacturers, distributors, pharmacy operators and consultants have agreed to pay to resolve lawsuits and investigations over their roles in the drug addiction crisis. Publicis Health, a subsidiary of Publicis Groupe, agreed to pay $350 million to resolve claims by all U.S. states and territories that it helped OxyContin maker Purdue Pharma devise marketing strategies to boost sales of its prescription opioid painkiller.

Reuters 2 months ago

PUBGY

HKMPY
Hikma Pharmaceuticals PLC's (LON:HIK) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Hikma Pharmaceuticals (LON:HIK) has had a great run on the share market with its stock up by a significant 6.2% over...

Simply Wall St. 2 months ago

HKMPY
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

PALO ALTO, Calif., January 08, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC ("Hikma"), a multinational pharmaceutical company, today announced an agreement to promote Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across all solid cancers in countries across the Middle East and North Africa (MENA).

Business Wire 3 months ago

HKMPF

HKMPY

GH
Are Investors Undervaluing Hikma Pharmaceuticals PLC (LON:HIK) By 26%?

Key Insights Hikma Pharmaceuticals' estimated fair value is UK£23.92 based on 2 Stage Free Cash Flow to Equity Hikma...

Simply Wall St. 3 months ago

HKMPY
Hikma Pharmaceuticals PLC's (LON:HIK) institutional investors lost 5.8% over the past week but have profited from longer-term gains

Key Insights Significantly high institutional ownership implies Hikma Pharmaceuticals' stock price is sensitive to...

Simply Wall St. 5 months ago

HKMPY
The one-year decline in earnings might be taking its toll on Hikma Pharmaceuticals (LON:HIK) shareholders as stock falls 3.3% over the past week

If you want to compound wealth in the stock market, you can do so by buying an index fund. But investors can boost...

Simply Wall St. 6 months ago

HKMPY
Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the US

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that on the two-year anniversary of its launch, it has now donated more than 375,000 doses of KLOXXADO® (naloxone HCl) nasal spray 8mg in the US – an important milestone in its ongoing work to help combat the opioid overdose epidemic.

PR Newswire 6 months ago

HKMPF

HKMPY
Are Strong Financial Prospects The Force That Is Driving The Momentum In Hikma Pharmaceuticals PLC's LON:HIK) Stock?

Hikma Pharmaceuticals (LON:HIK) has had a great run on the share market with its stock up by a significant 12% over the...

Simply Wall St. 7 months ago

HKMPY
Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North Africa

Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform today announces an exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company for the Middle East and North Africa (MENA).

PR Newswire 8 months ago

HKMPF

HKMPY
Is It Worth Considering Hikma Pharmaceuticals PLC (LON:HIK) For Its Upcoming Dividend?

Readers hoping to buy Hikma Pharmaceuticals PLC ( LON:HIK ) for its dividend will need to make their move shortly, as...

Simply Wall St. 8 months ago

HKMPY
Trending tickers: LSE | Rolls-Royce | Hikma | BMW

A look at the stocks making headlines on Thursday.

Yahoo Finance UK 8 months ago

GBPEUR=X

GBP=X

EUR=X
Hikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseases

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that its venture capital arm, Hikma Ventures, has invested in Octave Bioscience, the developer of a first-of-its-kind platform to accurately and objectively measure and help manage complex and high-cost neurodegenerative diseases, starting with multiple sclerosis (MS).

PR Newswire 8 months ago

HKMPF

HKMPY
Estimating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Hikma Pharmaceuticals fair value estimate is UK£22.12 With...

Simply Wall St. 9 months ago

HKMPY

Performance Overview

Return	HIK.L	FTSE 100
YTD	+3.85%	+3.97%
1-Year	+2.42%	+1.60%
3-Year	-17.94%	+15.88%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Hikma Pharmaceuticals PLC (HIK.L)

With 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big guns

Optimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past week

Merck's Bridion faces generic threat from drugmaker Hikma

Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility

High-dose opioid reversal spray no better than lower dose in field, US study finds

Hikma announces US launch of COMBOGESIC® IV

UPDATE 1-Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 million

Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 million

Hikma Pharmaceuticals PLC's (LON:HIK) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

Are Investors Undervaluing Hikma Pharmaceuticals PLC (LON:HIK) By 26%?

Hikma Pharmaceuticals PLC's (LON:HIK) institutional investors lost 5.8% over the past week but have profited from longer-term gains

The one-year decline in earnings might be taking its toll on Hikma Pharmaceuticals (LON:HIK) shareholders as stock falls 3.3% over the past week

Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the US

Are Strong Financial Prospects The Force That Is Driving The Momentum In Hikma Pharmaceuticals PLC's LON:HIK) Stock?

Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North Africa

Is It Worth Considering Hikma Pharmaceuticals PLC (LON:HIK) For Its Upcoming Dividend?

Trending tickers: LSE | Rolls-Royce | Hikma | BMW

Hikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseases

Estimating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Performance Overview